Re:23andMe has signed a $300M deal with GlaxoSmithKline
by carbocation on Saturday January 05, 2019 @06:16PM
(#18834990)
> Sequence data has more potential than GWAS ever had, e.g. finding rare mutations.
Sequencing studies really don't show this.
Sequencing finds rare variants. GWAS finds loci with common variants. We know that for many common diseases, the population-level variability due to rare variants is small. If you want to find drug targets, there is plenty of reason to use both approaches.
Sequencing studies really don't show this.
Sequencing finds rare variants. GWAS finds loci with common variants. We know that for many common diseases, the population-level variability due to rare variants is small. If you want to find drug targets, there is plenty of reason to use both approaches.